Ublituximab + Teriflunomide + Oral Placebo + IV Placebo

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Relapsing Multiple Sclerosis (RMS)

Conditions

Relapsing Multiple Sclerosis (RMS)

Trial Timeline

Aug 25, 2017 → Nov 12, 2020

NCT ID

NCT03277248

About Ublituximab + Teriflunomide + Oral Placebo + IV Placebo

Ublituximab + Teriflunomide + Oral Placebo + IV Placebo is a phase 3 stage product being developed by TG Therapeutics for Relapsing Multiple Sclerosis (RMS). The current trial status is completed. This product is registered under clinical trial identifier NCT03277248. Target conditions include Relapsing Multiple Sclerosis (RMS).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03277261	Phase 3	Completed	Sep 19, 2017	Nov 6, 2020	Relapsing Multiple Sclerosis (RMS)
NCT03277248	Phase 3	Completed	Aug 25, 2017	Nov 12, 2020	Relapsing Multiple Sclerosis (RMS)

Competing Products

20 competing products in Relapsing Multiple Sclerosis (RMS)

See all competitors

Product	Company	Stage	Hype Score
Placebo + Pirtobrutinib	Eli Lilly	Phase 2	52
CT-P53 + US-Ocrevus + EU-Ocrevus	Celltrion	Phase 3	77
LY2127399 + Placebo	Eli Lilly	Phase 2	52
dirucotide + placebo	Eli Lilly	Phase 2/3	65
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	52
Daclizumab	AbbVie	Phase 3	77
BIIB019 (Daclizumab High Yield Process) + Placebo	AbbVie	Phase 2	52
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccine	AbbVie	Phase 2	52
BIIB019 (Daclizumab)	AbbVie	Phase 3	77
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process Placebo	AbbVie	Phase 3	77
Rebif (Interferon beta-1a)	Merck	Pre-clinical	23
Interferon beta-1a	Merck	Pre-clinical	23
Rebif New Formulation + prophylactic Ibuprofen + Rebif New Formulation + ibuprofen PRN	Merck	Phase 3	77
Rebif® + Avonex®	Merck	Phase 3	77
Rebif® + Rebif®	Merck	Approved	85
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) alone	Merck	Phase 2	52
Placebo + IFN beta-1a + Methylprednisolone	Merck	Phase 2	52
Interferon beta-1a (Rebif)	Merck	Approved	85
Teriflunomide + Evobrutinib	Merck	Phase 3	77
Cladribine + Placebo + Microgynon®	Merck	Phase 1	33

Other Products from TG Therapeutics

UblituximabApproved

Ublituximab + OcrelizumabApproved

Ublituximab + Teriflunomide + Oral Placebo + IV PlaceboPhase 3

Ublituximab + PlaceboPhase 3

Obinutuzumab + Ublituximab + TGR-1202 + ChlorambucilPhase 3